Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC

Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC ( Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA )
16 Apr 2021

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )
16 Apr 2021

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development

Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )
13 Apr 2021

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )
9 Apr 2021

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD  II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Prof Ales Ryska - Charles University, Prague, Czech Republic
Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )
29 Mar 2021

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )
29 Mar 2021

Challenges and solutions in PD-L1 testing in NSCLC

Prof Frédérique Penault-Llorca - Centre Jean Perrin, Clermont-Ferrand, France
Challenges and solutions in PD-L1 testing in NSCLC ( Prof Frédérique Penault-Llorca - Centre Jean Perrin, Clermont-Ferrand, France )
5 Mar 2021

Current treatment standards for primary ovarian cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Current treatment standards for primary ovarian cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
18 Feb 2021

Evolving medical treatment in advanced/recurrent endometrial cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Evolving medical treatment in advanced/recurrent endometrial cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
18 Feb 2021